This book aims to bring together clinical information on the biology, diagnosis, therapy and management of patients with inflammatory breast cancer. Authored by experts from the Instituto Nacional de Cancerologia in Mexico, this book will provide the reader with the state-of-the art treatment of this rare but pernicious disease.

The book is the first one published exclusively on the field of nutritional epidemiology of breast cancer. It summarizes the currently existing knowledge, with an updated and comprehensive international bibliography (~ 1.000 references). The authors also performed a review on the epidemiological studies on nutrition and breast cancer carried out in Uruguay between 1994 and 2011, which allowed exploring and identifying the main risk and protective factors for the disease in this high-risk country. Epidemiologists, Nutritionists, Public Health managers and breast specialists -from the prevention to the treatment fields - will find in this book a unique source of technical information, which will contribute in expanding their knowledge and view of the disease.

This volume will describe both growth-inhibitory and mucin-depleting effects of bromelain and N-acetylcysteine, on their own or in combination, in cancer. It will coherently review the pathophysiological aspects of the mucin glycoproteins in malignancies and provide an updated account of the status of bromelain and N-acetylcysteine in cancer therapy. The volume will develop the idea of using these two drugs as a combination formulation for mucin-depleting effects.

"Advances in Cancer Research" provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics.
113th volume of Advances in Cancer ResearchExpert authorsChapters on topics including microRNA regulatory network, multifaceted oncoprotein tax, and underlying chromosomal translocations

Topics in this issue?include: Targeting IGF-1R; Tyrosine Kinase Inhibitors in Lung Cancer; Targeting mTOR; Targeting Hedgehog; Mitotic Inhibitors; Topoisomerase I Inhibitors; and New Strategies and Drugs Inhibiting Folate Pathways.

The aim of this issue is to provide the thoracic surgeon with information about the staging and treatment of cancer to the mediastinal lymph nodes. The issue includes articles on the anatomy and physiology of the lymph nodes, imaging of the lymph nodes, and various techniques for diagnosing and dissecting the lymph nodes, including video-assisted mediastinoscopic lymphadenectomy and transcervical extended mediastinal lymphadenectomy.

Photon Radiation Therapy for Skin Malignancies is a vital resource for dermatologists interested in radiation therapy, including the physics and biology behind treatment of skin cancers, as well as useful and pragmatic formulas and algorithms for evaluating and treating them. Dermatology has always been a field that overlaps multiple medical specialties and this book is no exception, with its focus on both dermatologists and radiation oncologists. It is estimated that between 2010 and 2020, the demand for radiation therapy will exceed the number of radiation oncologists practicing in the U.S. tenfold, which could profoundly affect the ability to provide patients with sufficient access to treatment. Photon Radiation Therapy for Skin Malignancies enhances the knowledge of dermatologists and radiation oncologists and presents them with the most up-to-date information regarding detection, delineation and depth determination of skin cancers, and appropriate biopsy techniques. In addition, the book also addresses radiation therapy of the skin and the skin's reactions to radiation therapy.

Natural History of Vestibular Schwannomas (includes histology, epidemiology); Clinical and Diagnostic Evaluation (includes cost effectiveness of imaging vs audiometry); Neurophysiological Correlates: Preoperative, Intraoperative and Postoperative - Facial nerve, Auditory function, Vestibular; Neurofibromatosis Type 2 and Genetics; Art of Management Decision Making: From Intuition to Evidence Based Medicine (includes analysis of various decision making strategies); Radiation Therapy and Radiosurgery: Indications, Techniques and Results (CK, GK, LINAC,etc...); Management of Radiation/Radiosurgical Complications and Failures; Retrosigmoid Approach: Indications, Techniques and Results; Translabyrinthine Approach: Indications, Techniques and Results; Middle Fossa Approach: Indications, Techniques and Results; Endoscopic Approach: Indications, Techniques and Results; Management of Surgical Complications and Failures; Chemotherapy: Present and Future (new trials of Avastin and similar drugs); Habilitation of Auditory and Vestibular Dysfunction (Baha, vestibular rehab, etc.); Habilitation of Facial Nerve Dysfunction (neural grafts, muscle transfers, etc...); Support Groups and Patient Resources (Acoustic Neuroma Association, Neurofibromatosis Society)

Topics in this issue?include: Why does my patient have leukocytosis?; Why Is My Patient Neutropenic?; Does My Patient with a Serum Monoclonal Spike have Multiple Myeloma?; DVT and Pulmonary Embolism; Why Does My Patient Have Lymphadenopathy/Splenomegaly?; and Why Does My Patient have Thrombocytopenia?

This issue of the Urologic Clinics provides a timely update on Renal Cancer and the evolving treatment standards in urology.? Articles include Contemporary Imaging of the Renal Mass, Surgical Approach to Multifocal Renal Cancers, and Systemic Therapy Prior to Surgery.? Effects of the various existing surgical approaches on long-term renal function is also discussed, along with a review of the current trends in surgical management of renal cancers with specific attention to utilization of laparoscopic approach, partial nephrectomy, ablative technologies and observation.

This issue serves as a comprehensive review and update in the management of the geriatric cancer patient. Topics covered include: Cancer and Aging, Comprehensive Geriatric Assessment, Breast Cancer in the Elderly, Solid Tumors in the Elderly, Radiation Therapy with the Elderly, Liquid Tumors in the Elderly, Nursing and Palliation of Elderly Cancer Patients, Ethics and Religion in Care of the Elderly, and Surgery in the Elderly.

This book collates past and current research on one of the most promising emerging modalities for breast cancer detection. Readers will discover how, as a standalone technology or in conjunction with another modality, microwave imaging has the potential to provide reliable, safe and comfortable breast exams at low cost. Current breast imaging modalities include X- ray, Ultrasound, Magnetic Resonance Imaging, and Positron Emission Tomography. Each of these methods suffers from limitations, including poor sensitivity or specificity, high cost, patient discomfort, and exposure to potentially harmful ionising radiation. Microwave breast imaging is based on a contrast in the dielectric properties of breast tissue that exists at microwave frequencies. The book begins by considering the anatomy and dielectric properties of the breast, contrasting historical and recent studies. Next, radar-based breast imaging algorithms are discussed, encompassing both early-stage artefact removal, and data independent and adaptive beamforming algorithms. In a similar fashion, microwave tomographic reconstruction algorithms are reviewed in the following chapter, introducing the reader to both the fundamental and more advanced algorithms. Apart from imaging, the book also reviews research efforts in extracting clinically useful information from the Radar Target Signature of breast tumours, which is used to classify tumours as either benign or malignant. Finally, the book concludes by describing the current state of the art in terms of prototype microwave breast imaging systems, with a particular emphasis on those which have progressed to the clinical evaluation stage. This work is motivated by the fact that breast cancer is one of the leading causes of death amongst women in Europe and the US, and the second most common cancer in the world today. Such an important area of research will appeal to many scholars and practitioners.p>

Various aspects, including diagnosis, therapy, and prognosis, of two brain tumors (meningioma and schwannoma) , of brain tumors are discussed in this volume. Insights on the understanding of molecular pathways involved in brain tumor biology are explained. For example, the role of E-cadherin gene instability, carbonic anhydrase 11, urokinase plasminogen activator, and Wnt signaling is discussed in detail. Such information will lead to the development of effective aniicancer drugs. The role of molecular genetics and epigenetic mechanisms in schwannomas is explained. Also, is explained the role of cyclin D1 in vestibular schwannoma. The determination of subtypes of meningiomas using perfusion magnetic resonance imaging is explained. Diagnosis of incidentally discovered meningioma and cystic papillary meningioma is also included. Diagnosis of facial nerve schwannoma, vestibular schwannoma, and intermediate nerve schwannoma is explained. Treatments for atypical meningioma, oncocytic meneingioma, intracranial meningioma, and cavernous are presented. Therapeutic methods such as neurosurgery, Gamma knife radiosurgery, and adjuvant radiation for this cancer are included. Large number of other treatments, including radiosurgery, retrosigmoidal craniotomy, and immunotherapy, for vestibular schwannoma patients are detailed.

This volume, a state-of-the-art review of early phase clinical trials for cancer immunotherapy, discusses biomarker selection, combinatorial strategies and their safety or toxicity, determination of Phase 2 dosing, endpoints in the setting of radiographic pseudoprogression, histology selection, and novel immunotherapeutics as they relate to early phase cancer immunotherapy.

The difference among pluripotent stem cells, multipotent stem cells, and unipotent stem cells is pointed out. Vast therapeutic applications of the following specific stem cells in disease and tissue injury are discussed: human embryonic stem cells, human mesenchymal stem cells, germ cell-derived pluripotent stem cells, induced pluripotent stem cells, human umbilical cord blood-derived stem cells, breast tumor stem cells,and hematopoietic stem cells. Because of the potential of human embryonic stem cells to produce unlimited quantities of any human cell type, considerable focus is placed on their therapeutic potential. Because of their pluripotency, these cells have been used in various applications such as tissue engineering, regenerative medicine, pharmacological and toxicological studies, and fundamental studies of cell differentiation. The formation of embryoid bodies, which are three-dimensional aggregates of embryonic stem cells, is explained as this is the first step in cell differentiation. Such embryoid body culture has been widely used as a trigger for the in vitro differentiation of embryonic stem cells. The basic capacity of self-renewal of human embryogenic stem cells is explained. The role of TGF-beta in the propagation of human embryonic stem cells is discussed. The differentiation of human embryonic stem cells into neurons, hepatocytes, cardiomyocytes, and retinal cells is fully explained. Donor policies for hematopoietic stem cells are also explained.

Dr. Van Dam is an internationally recognized leader in gastroenterology and has been a leader in advances in intervedntional endoscopy. He brings this expertise to the topic of management of benign and malignant pancreatic disease and has selected top experts in the field to provide state-of-the-art clinical information to gastroenterologists. The modern management treatise of each article addresses current diagnostics as well as medical management. Seven articles are devoted to pancreatic cancer and span medical management, surgial mangament, radiologic imaging, endoscopic diagnosis, palliation, and screening. Other important topics addressed are pancreatic transplantation, pancreatic cystic neoplasms, acute and chronic pancreatitis, and autoimmune pancreatitis.

This issue of Clinics in Laboratory Medicine includes the following topics: Detection of cancer biomarkers by cerium oxide nanoparticles; Quantum dot-based assays for cancer biomarkers; Monoclonal antibody conjugated fluorescent magnetic nanoparticles for in vivo diagnosis of cancer; RNA quantification with gold nanoprobes for cancer diagnostics; Nanostructured silica materials for imaging in cancer; and Nanoparticle-based cancer cell sorting.

Carcinoma of the lung is one of the most prevalent and aggressive types of cancer, and rates of lung cancer are on the rise.? This issue gives a comprehesive review of the most recent advances in Lung Cancer.? Epidemiology, etiology, and prevention of lung cancer is first discussed, followed by articles on pre-invasive evaluation and management, screening, pathology and molecular biology.? There is an article on the approach to the ground glass nodule.? Of great importance is the revised staging classification of Lung Cancer, which is discussed here in detail.? Articles on PET imaging, interventional pulmonary, and functional evaluation before Lung Resection are also included.? The issue then focuses on advances in treatment for early stage lung cancer, hgih risk patients with early stage lung cancer, advances in the treatment of Advanced Stage Lung Cancer, Small Cell Lung Cancer, and gene therapy for lung neoplasms.

New research has shown that neuroendocrine tumors are more common than previously thought. Progress in our understanding of the molecular pathogenesis of these not-so-rare cancers has resulted in renewed interest in developinginnovative therapeutic options. In particular, novel molecular targeted agents have been shown to have significant anti-tumor activity, and integration of these therapies has led to critical advances in management.

In this volume, an outstanding group of the world s leaders in the field have assembled to convey their knowledge of the epidemiology, biology, and management of allthemajor types of neuroendocrine tumors. The book takes a multi-modality approach to understanding disease processes and therapeutics, including chapters on medical and surgical treatment as well as a chapter devoted to imaging. Throughout, the authors emphasize recent advances in our understanding of molecular biology and the subsequent emerging therapeutic options.

This volume highlights recent developments in neuro-oncology that are not only increasing the survival rate of patients, but also improving their quality of life. Through an in-depth exploration of new therapies, including advanced diagnostic tools and a fresh perspective on molecular biology, immunology, and the clinical aspects of tumors, clinicians will gain a critical understanding of emerging therapies and techniques. Extensive coverage of tumor management and new therapeutic strategies, including gene therapy and molecularly targeted treatments are also explored, providing clinicians with new tools and tactics they can use to treat tumors of the nervous system.

Clinicians will find this handbook to be an invaluable resource for summarizing the present state of scientific and clinical knowledge in the field of neuro-oncology. In addition, practitioners in the field will uncover new tactics and therapies that will aid them in providing optimal neuro-oncological care for their patients.
* An invaluable resource that includes critical, in-depth insights into recent developments in neuro-oncology
* A fresh perspective on molecular biology, immunology, and other clinical aspects of tumors of the nervous system
* Extensive coverage of tumor management and new therapeutic strategies, including gene therapy and molecularly targeted treatments
* New tactics and therapies that will aid clinicians in their quest to provide optimal care for their neuro-oncological patients

Handbook of Clinical Neurology: Neuro-Oncology, Part II provides an overview of the most recent developments in the field of neuro-oncology, including new diagnostic imaging techniques, along with immunology, molecular biology, and clinical aspects of different types of tumors. It also considers management and new therapeutic strategies for tumors, such as gene therapy, radiation therapy, and molecularly targeted treatments. Divided into five sections encompassing 33 chapters, the book begins with a description of specific tumor types such as low-grade gliomas, anaplastic astrocytomas, and medulloblastoma and primitive neuroectodermal tumors, along with rare brain tumors like neurofibromatosis and other genetic syndromes. It then discusses tumors at special sites, from brainstem tumors to peripheral nerve tumors, tumors of the meninges, and optic, hypothalamic, and thalamic tumors. It also explains the neurological complications of systemic cancer and the adverse effects of some treatments. Clinicians and neuroscientists, as well as researchers who read this book, will gain a better understanding of the clinical features and management of the neurological manifestations of tumors.

Dr. Talpaz has assembled top experts to write state-of-the art reviews on the management of chronic myelogenous leukemia. Some of the articles that will be of most interest include Selection of Therapy: Rational Decisions Based on Molecular Events; Is There a Potential Cure for CML in Current Therapies?; Hurdles Toward a Cure for CML: The CML Stem Cell; The CML Stem Cell in the Chronic and Advanced Disease; CML Disease Progression; Management of Ph+ ALL and CML Blast Crisis; BMT in CML in the Era of Targeted Therapy; Pharmacoeconomics: The Cost of Staying Alive; and The Significance of CML Prognostic Factors in the Era of Targeted Therapy.

This volume of the Urologic Clinics covers the indications, controversies, and complications of Lymphadenectomy in Urologic Oncology.? Cancer of the prostate, bladder, testicles, and kidney are covered, along with new imaging modalities and complications of open and minimally invasive lymphadenectomy.

Topics for this issue will include: CLL: ? A Historical Perspective; Incidence & Epidemiology; Biology, Molecular Biology & Cytogenetics of CLL; What does the status of smatic hypermutations in IGVH genes tell us about the origin of CLL?; What does the status of ZAP-70 tell us about the biology of CLL?; and Approach to initial therapy: When to start therapy?